Press Release / Business / Global Rheumatoid Arthritis Market is Estimated to Reach $3.2 Billion by 2025, Says Accurize Market Research

Global Rheumatoid Arthritis Market is Estimated to Reach $3.2 Billion by 2025, Says Accurize Market Research

Global Rheumatoid Arthritis Market report published by Accurize Market Research forecast that the global market is expected to reach $3.2 billion by 2025; growing at a CAGR of 6.8% from 2017 to 2025. By geography, Asia Pacific and North America are expected to grow at a CAGR of XX% and XX%, respectively, during the forecast period.

Request Sample:
https://www.accurizemarketresearch.com/report/drugs-for-rheumatoid-arthritis-market/sample-request

Upsurge in number of hospitals and growth in preference of the geriatric patient population to undergo treatment at hospitals to drive the growth of the market

Upsurge in number of hospitals and growth in preference of the geriatric patient population to undergo treatment at hospitals, need to maximize patient safety and technological advancements in healthcare fuel the demand for the global rheumatoid arthritis market. Furthermore, increasing awareness for health related issues and biotechnological research and developments in rheumatoid arthritis drugs also boosts the growth of the market.

Market Segmentation

The global rheumatoid arthritis market has been bifurcated on the basis of drug type, distribution channel, and geography. Drug Type is categorized into nonsteroidal anti-inflammatory drugs (NSAIDS), corticosteroids, disease modifying anti-rheumatic drugs (DMARDS)and biologic response modifiers (Biologics). Furthermore, distribution channel is bifurcated as hospital pharmacy, retail pharmacy and online pharmacy. By geography the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW).

Request Customization:
https://www.accurizemarketresearch.com/report/drugs-for-rheumatoid-arthritis-market/ask-for-customization


Top players in the market

The key players operational in the market includes Abbvie, Ablynx, Alder Biopharmaceuticals, Amgen, Bristol-Myers Squibb, Centocor, Daiichi Sankyo, Eli Lilly, Galapagos NV, Genentech (Roche), Gilead, GlaxoSmithKline, Incyte Corp., Janssen Biotech, Johnson & Johnson, Medimmune, Merck & Co., Pfizer, Regeneron, Sanofi and Ucb among others.